Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Trial Profile

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Providence Health & Services
  • Most Recent Events

    • 27 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 15 Jan 2018.
    • 26 Oct 2017 Planned End Date changed from 1 Sep 2026 to 1 Dec 2026.
    • 26 Oct 2017 Planned primary completion date changed from 1 Sep 2025 to 1 Dec 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top